Related Experiment Video
Updated: Jun 26, 2025
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Recent advances in c-Met-based dual inhibitors in the treatment of cancers
Fanqi Jin1, Yihan Lin1, Weidong Yuan1
1College of Pharmacy of Liaoning University, Shenyang, Liaoning, 110036, PR China.
Abstract:
The cellular-mesenchymal epithelial transition factor (c-Met) is a receptor tyrosine kinase (RTK) located on the 7q31 locus encoding the Met proto-oncogene and plays a critical role in regulating cell proliferation, metastasis, differentiation, and apoptosis through various signaling pathways. However, its aberrant activation and overexpression have been implicated in many human cancers. Therefore, c-Met is a promising target for cancer treatment. However, the anticancer effect of selective single-targeted drugs is limited due to the complexity of the signaling system and the involvement of different proteins and enzymes. After inhibiting one pathway, signal molecules can be transmitted through other pathways, resulting in poor efficacy of single-targeted drug therapy. Dual inhibitors that simultaneously block c-Met and another factor can significantly improve efficacy and overcome some of the shortcomings of single-target inhibitors, including drug resistance. In this review, We introduced c-Met kinase and the synergism between c-Met and other anti-tumor targets, then dual-target inhibitors based on c-Met for the treatment of cancers were summarized and their design concepts and structure-activity relationships (SARs) were discussed elaborately, providing a valuable insight for the further development of novel c-Met-based dual inhibitors.
Insights
Dual inhibitors targeting c-Met (cellular-mesenchymal epithelial transition factor) and other factors show improved cancer treatment efficacy. This approach overcomes limitations of single-target drugs by blocking multiple pathways, enhancing outcomes and reducing resistance.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- The receptor tyrosine kinase c-Met (cellular-mesenchymal epithelial transition factor) is crucial for cell regulation but its aberrant activation drives many cancers.
- Single-targeted drugs inhibiting c-Met have limited efficacy due to complex signaling networks and compensatory pathways.
- Drug resistance is a significant challenge in c-Met-targeted cancer therapy.
Purpose of the Study:
- To review the role of c-Met kinase in cancer.
- To explore the synergistic potential between c-Met and other anti-tumor targets.
- To summarize dual-target inhibitors based on c-Met for cancer treatment, including their design and structure-activity relationships (SARs).
Main Methods:
- Literature review of c-Met signaling pathways and cancer involvement.
- Analysis of dual-target inhibitor strategies for c-Met.
- Discussion of design concepts and structure-activity relationships (SARs) for novel dual inhibitors.
Main Results:
- Dual inhibitors blocking c-Met and another target demonstrate enhanced efficacy compared to single-target agents.
- Simultaneous inhibition overcomes pathway redundancy and mitigates drug resistance.
- Detailed SARs provide insights into optimizing dual-target inhibitor design.
Conclusions:
- Dual-target inhibitors based on c-Met offer a promising strategy to improve cancer treatment outcomes.
- Understanding c-Met synergism and SARs is vital for developing next-generation cancer therapies.
- This review provides a valuable foundation for the development of novel c-Met-based dual inhibitors.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:38Mitogens and the Cell Cycle
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...